MapLight Therapeutics planned sale of 33,605 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
MapLight Therapeutics, Inc. reports that Anatol Kreitzer has filed a notice to sell up to 33,605 shares of MapLight voting common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of 1273966.00, around July 15, 2026 on Nasdaq.
Shares of this class outstanding were 42,618,165. During the past three months, Kreitzer sold 3,316 shares for 88239.00 on April 15, 2026 and 45,422 shares for 1347066.00 on April 27, 2026.
Key Figures
Key Terms
Restricted stock unit settlement financial
aggregate market value financial
Securities Sold During The Past 3 Months regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stock sale is disclosed for MapLight Therapeutics (MPLT)?
What prior sales did Anatol Kreitzer report for MapLight Therapeutics (MPLT)?
AI-generated analysis. How Rhea-AI works. Not financial advice.